ArticleNeuro-oncology2025
A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence.
Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A multidisciplinary program for meningioma treatment, research, and support services.Neuro-oncology practice · 2026Article
- Multidisciplinary management of meningiomas in the era of precision oncology.Nature reviews. Clinical oncology · 2026Review
- A proteogenomic RNA processing mechanism drives sex differences in meningioma.Research square · 2026Article
- Rational Radionuclide Therapy for Recurrent Meningioma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Combined SSTR2-targeted Analogue withFrontiers in oncology · 2026Article
- Preoperative embolization improves local control and modulates gene expression in atypical WHO grade 2 meningioma.Neuro-oncology · 2025Article
- Determining the Biological Features of Aggressive Meningioma Growth with Transcriptomic Profiling.Cancers · 2025Article
- Postoperative radiotherapy in subtotally resected recurrent WHO grade 1 meningiomas with intermediate-/high-risk molecular profiles.Neuro-oncology · 2025Article
- The Rationale for Early Adjuvant Radiotherapy After Gross Total Resection of Atypical Meningioma.Neurosurgery · 2025Article
- Meningioma: Novel Diagnostic and Therapeutic Approaches.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDespite reassuring clinical and histological features, low-grade meningiomas can recur after surgery. Targeted gene expression profiling improves risk stratification of meningiomas, but the utility of this approach for clinical low-risk meningiomas is incompletely understood.
methodsThis was a multicenter retrospective cohort study of meningiomas from patients who were treated at 4 institutions from 1992 to 2023. Adult patients with newly diagnosed or recurrent World Health Organization (WHO) grade 1 meningiomas that were treated with gross total resection (GTR) or subtotal resection (STR), or newly diagnosed WHO grade 2 meningiomas that were treated with GTR, were included. A 34-gene expression biomarker and gene expression risk score (continuous from 0 to 1) was evaluated in all samples.
resultsThe study cohort was comprised of 723 patients, none of which were used for discovery or training of the gene expression biomarker and 265 of which were previously unreported. There were 626 WHO grade 1 meningiomas, 490 with GTR and 126 with STR, and 97 WHO grade 2 meningiomas with GTR. Targeted gene expression profiling classified 51.3% of clinical low-risk meningiomas as molecular intermediate-risk and 9.5% as molecular high-risk. Combining the gene expression biomarker with the extent of resection revealed that 19.8% of clinical low-risk meningiomas had unfavorable local freedom from recurrence (LFFR) and overall survival (OS), including 7.1% of newly diagnosed WHO grade 1 meningiomas with GTR. The risk score was prognostic for LFFR (HR per 0.1 increase in risk score 1.89, 95% CI: 1.58-2.25) across all WHO grades, extents of resection, and newly diagnosed or recurrent presentations.
conclusionsTargeted gene expression profiling can identify clinical low-risk meningiomas that are likely to recur after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.